INTRODUCTION

B-cell chronic lymphocytic leukemia/lymphoma (B-CLL/L) is an indolent hematologic malignancy characterized by chronic lymphocytic leukemia.

Zanubrutinib is a new generation BTK inhibitor designed to maintain BTK occupancy and minimize off-target kinase activity, which may contribute to the profound effects of this drug class.

AIMS & OBJECTIVES

The primary objective was to assess the safety of zanubrutinib in patients with WM. As a secondary objective, the efficacy of zanubrutinib was evaluated in patients with WM.

RESULTS

- Thirty-eight (76.0%) patients experienced ≥1 TEAE of interest.
- Nineteen (38.0%) patients experienced ≥1 TEAE (N=50).
- The higher rate of PD and thus lower ORR compared to that of ASPEN, may be explained by differences in the population and duration of follow-up.

CONCLUSIONS

- Zanubrutinib is an effective treatment for patients with intermediate or high-risk R/R or TN WM and other B-cell malignancies when established zanubrutinib profile in WM and other B-cell malignancies when

Efficacy

- The ORR was 31.8% (95% CI 23.8-40.8) in patients with ≥1 response evaluations while on study (efficacy evaluable, n=41; investigator's decision (n=1) and other (n=1)).
- The overall median duration of treatment exposure was 9.20 months (range 0.50-24.50).

Safet

- The most common TEAEs were arthralgia, fatigue, pruritus, and skin hemorrhage (each n=1). The most common TEAEs were arthralgia, fatigue, pruritus, and skin hemorrhage (each n=1).
- The most common serious TEAEs were pericardial effusion, pleural effusion, skin hemorrhage, and soft tissue sarcoma (each n=1).

REFERENCES


ACKNOWLEDGMENTS

- This study was sponsored by BeiGene. Editorial support was provided by Bio Connections LLC and funded by BeiGene.
- jorgej_castillo@dfci.harvard.edu

ABREVIATIONS

- BID: twice daily
- BMT: Bone marrow transplantation
- CLL: Chronic lymphocytic leukemia
- DFS: Disease-free survival
- ORR: Objective response rate
- PD: Progression of disease
- R/R: Refractory or resistant
- TN: Treatment-naive
- WHO: World Health Organization
- WM: Waldenström Macroglobulinemia

CONTACT

Dr. HAY

E-mail: hay@imasun.meduniwien.ac.at